药械指南

订阅

MedSci主页 / 所有栏目 / 药械指南

FDA 生物样品分析方法验证指导原则 2018

2018-08-23 美国食品和药品监督管理局 FDA

指导原则

FDA 生物样品分析方法验证指导原则

中文标题：

FDA 生物样品分析方法验证指导原则 2018

发布机构：

美国食品和药品监督管理局

发布日期：

2018-08-23

简要介绍：

FDA 生物样品分析方法验证指导原则

相关资料下载：
[AttachmentFileName(sort=1, fileName=Bioanalytical.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c5a351c0021a5e52, title=FDA 生物样品分析方法验证指导原则 2018, enTitle=, guiderFrom=FDA, authorId=0, author=, summary=FDA 生物样品分析方法验证指导原则, cover=, journalId=0, articlesId=null, associationId=486, associationName=美国食品和药品监督管理局, associationIntro=美国食品和药品监督管理局是美国公共卫生及服务部的一个代理商，其由委员会办公室和4个监督核心功能理事机构组成。, copyright=0, guiderPublishedTime=Thu Aug 23 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<p>FDA&nbsp;生物样品分析方法验证指导原则</p>, tagList=[TagDto(tagId=26642, tagName=指导原则)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3100, appHits=37, showAppHits=0, pcHits=1156, showPcHits=3063, likes=0, shares=8, comments=3, approvalStatus=1, publishedTime=Tue Aug 03 18:14:16 CST 2021, publishedTimeString=2018-08-23, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=fbzhang, createdTime=Tue Aug 03 18:13:00 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 16:11:43 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=Bioanalytical.pdf)])
Bioanalytical.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1071525, encodeId=4f1a10e1525ea, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67795720844, createdName=ms9000000565017997, createdTime=Thu Nov 18 20:09:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005048, encodeId=28fa100504849, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 04 09:14:48 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004943, encodeId=4665100494351, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f95542972, createdName=beautifullive, createdTime=Tue Aug 03 19:35:58 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
    2021-11-18 ms9000000565017997

    谢谢！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1071525, encodeId=4f1a10e1525ea, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67795720844, createdName=ms9000000565017997, createdTime=Thu Nov 18 20:09:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005048, encodeId=28fa100504849, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 04 09:14:48 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004943, encodeId=4665100494351, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f95542972, createdName=beautifullive, createdTime=Tue Aug 03 19:35:58 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
    2021-08-04 智慧药

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1071525, encodeId=4f1a10e1525ea, content=谢谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67795720844, createdName=ms9000000565017997, createdTime=Thu Nov 18 20:09:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005048, encodeId=28fa100504849, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Aug 04 09:14:48 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004943, encodeId=4665100494351, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42f95542972, createdName=beautifullive, createdTime=Tue Aug 03 19:35:58 CST 2021, time=2021-08-03, status=1, ipAttribution=)]
    2021-08-03 beautifullive

    不错

    0

相关指南

以临床价值为导向的抗肿瘤药物临床研发指导原则（征求意见稿）

国家药品监督管理局药品审评中心（CDE） · 2021-07-02

托珠单抗注射液生物类似药临床试验指导原则

国家药品监督管理局药品审评中心（CDE） · 2021-04-21

放射性体内诊断药物非临床研究技术指导原则

国家药品监督管理局药品审评中心（CDE） · 2021-02-24

药品附条件批准上市技术指导原则（试行）

国家药品监督管理局药品审评中心（CDE） · 2020-11-26

药物临床试验期间安全性数据快速报告标准和程序

国家药品监督管理局药品审评中心（CDE） · 2018-07-01